VCBeat Health Contact Us
Home Sinocelltech's SCG101 Autologous T-cell Injection Receives IND Approval in China for HBV-Related Hepatocellular Carcinoma

Sinocelltech's SCG101 Autologous T-cell Injection Receives IND Approval in China for HBV-Related Hepatocellular Carcinoma

Mar 11, 2022 09:44 CST Updated 09:44
SCG Cell Therapy

Innovative Immunotherapy Developer

On March 10, the CDE website showed that SCG101 Autologous T-cell Injection from SCG SCIENCE (DALIAN) CO., LTD. successfully obtained clinical trial implied permission for the treatment of hepatitis B virus-related hepatocellular carcinoma.

1646962623756.png

1646962623891.png

1646962623952.png

*Disclaimer: This article was written by an author who has settled in Sina Medicine News. The views expressed represent the personal opinions of the author and do not reflect the position of Sina Medicine News.